Name: | Sotalol |
---|---|
PubChem Compound ID: | 119259 |
Description: | An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. |
Molecular formula: | C12H20N2O3S |
Molecular weight: | 272.365 g/mol |
Synonyms: |
Methanesulfonamide, N-(4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)phenyl)-, (S)-; 30236-32-9; Dexsotalol
|
Name: | Sotalol |
---|---|
Name (isomeric): | DB00489 |
Drug Type: | small molecule |
Description: | An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. |
Synonyms: |
Sotalol HCL
|
Brand: | Sorine, Betapace, Betapace AF |
Category: | Sympatholytics, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents |
CAS number: | 3930-20-9 |
Indication: | For the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias. |
---|---|
Pharmacology: |
Sotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs ...
show more » |
Mechanism of Action: |
Sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-...
show more » |
Absorption: | In healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal. |
Protein binding: | Sotalol does not bind to plasma proteins. |
Biotransformation: | Sotalol is not metabolized. |
Route of elimination: | Excretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk. |
Half Life: | Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life. |
Toxicity: | The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|